Workspace

Evidence workspace

Rank mutation signals, inspect pathway evidence, and prepare research-use hypotheses for expert review.

Active cohort: Lung adenocarcinoma demo cohort · 48 samples · 5 genes · Last scored 24m ago

Active cohort

Next step

Review the top-ranked mutation signals

The latest lung adenocarcinoma run produced 5 ranked signals and 6 draft hypothesis classes. Review the evidence trail before exporting the research brief.

Review ranked signalsRun new cohortOpen report draft →

5

Signals ranked

6

Hypotheses drafted

2

Accepted for report

2

Limitation unresolved

Highest-priority signal

EGFR L858R

EGFR/ERBB signalling

Strong pathway evidence · linked to EGFR inhibitor class.

Needs expert review before report export.

Inspect evidence trail

Review queue

6 evidence items

  • Ready for report2
  • Needs evidence check2
  • Limitation unresolved2

2 briefs already prepared for this cancer type.

Active samples

48

De-identified rows in cohort

Ranked signals

5

Mutation relevance rows

Draft hypotheses

6

Candidate research classes

Report-ready items

2

Accepted for research brief

Top mutation signals

Ranked for expert review

Open a signal to inspect matched gene, pathway, evidence category, limitation, and next validation step.

Open evidence board
RankSignalPathwayTierScoreReview state
1

EGFR L858R

EGFR inhibitor class

EGFR/ERBB signallingStrong94Ready for review
2

TP53 R175H

DNA damage response research marker

p53 tumour suppressor pathwayStrong88Needs interpretation
3

KRAS G12C

KRAS / MEK pathway inhibition

RAS/MAPK signallingModerate82Hypothesis drafted

Draft hypothesis classes

Candidate research shortlist

5 matched

Generated from matched pathway context. Research hypotheses only, not treatment recommendations.

EGFR inhibitor class

Linked to EGFR L858R · EGFR/ERBB signalling

Ready for review

KRAS / MEK pathway inhibition

Linked to KRAS G12D · RAS/MAPK signalling

Needs interpretation

KRAS / MEK pathway inhibition

Linked to KRAS G12C · RAS/MAPK signalling

Hypothesis drafted

MET pathway inhibitor class

Linked to MET Exon 14 skipping · RTK/MAPK signalling

Pending review

Cohort intake summary

Lung adenocarcinoma demo cohort

The uploaded file is de-identified and matches the required mutation schema. Detected genes were mapped into pathway-level evidence and prepared for ranking.

Cohort

Lung adenocarcinoma demo cohort

Cancer type

Lung adenocarcinoma

Samples

48

Genes detected

5

Input format

Annotated mutation table (VCF / CSV)

De-identification

Confirmed (demo)

Schema status

Validated

Last scored

24m ago

Pathway distribution

Relevance by pathway

Hover a pathway to inspect the top signal, candidate research class, and evidence tags. Counts reflect ranked rows in this cohort only.

1. Cohort intakeUpload or select a de-identified cohort.2. Mutation scoringRun pathway-aware relevance scoring.3. Evidence boardInspect ranked signals and limitations.4. Research briefExport reviewed evidence as a brief.
Research-use boundary

Keep the evidence trail visible before export.

Research-use only. ONCOQ.TECH supports research planning and expert review. Outputs are not clinical diagnoses, treatment recommendations, prescribing advice, or patient-level decisions. Downstream use requires qualified expert review, validated evidence sources, and appropriate governance.

Generate research brief